Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


pHAGE-PIK3CA Citations (2)

Originally described in: Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK, Li J, Jeong KJ, Shao S, Chen H, Tsang YH, Sengupta S, Wang Z, Bhavana VH, Tran R, Soewito S, Minussi DC, Moreno D, Kong K, Dogruluk T, Lu H, Gao J, Tokheim C, Zhou DC, Johnson AM, Zeng J, Ip CKM, Ju Z, Wester M, Yu S, Li Y, Vellano CP, Schultz N, Karchin R, Ding L, Lu Y, Cheung LWT, Chen K, Shaw KR, Meric-Bernstam F, Scott KL, Yi S, Sahni N, Liang H, Mills GB Cancer Cell. 2018 Mar 12;33(3):450-462.e10. doi: 10.1016/j.ccell.2018.01.021.
PubMed Journal

Articles Citing pHAGE-PIK3CA

PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway. Zhou J, Imani S, Shasaltaneh MD, Liu S, Lu T, Fu J. Mol Biol Rep. 2022 Mar;49(3):1799-1816. doi: 10.1007/s11033-021-06990-x. Epub 2021 Nov 23. PubMed
ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component. Jauhiainen S, Ilmonen H, Vuola P, Rasinkangas H, Pulkkinen HH, Keranen S, Kiema M, Liikkanen JJ, Laham-Karam N, Laidinen S, Beter M, Aavik E, Lappalainen K, Lohi J, Aronniemi J, Ord T, Kaikkonen MU, Salminen P, Tukiainen E, Yla-Herttuala S, Laakkonen JP. Elife. 2023 May 18;12:e82543. doi: 10.7554/eLife.82543. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.